#USA #New York #Gross Law Firm #Rocket Pharmaceuticals #RCKT

Class Action Lawsuit Filed Against Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is currently facing a class action lawsuit, as announced by The Gross Law Firm. The firm has called for shareholders who acquired RCKT shares within the specified period to consider registering as potential lead plaintiffs. Notably, taking on the lead plaintiff role is not a requisite to join and potentially benefit from any financial recovery related to the lawsuit.

Background of the Case

The class period for this lawsuit spans from February 27, 2025, to May 26, 2025. Allegations suggest that the company's management made significantly optimistic statements about their product, RP-A501, while simultaneously hiding severe drawbacks associated with its safety and protocols. Specifically, the complaint indicates that Rocket Pharmaceuticals concealed serious adverse events, which included patient fatalities during clinical trials.

Furthermore, the company allegedly altered the trial's protocol without informing investors, introducing a new immunomodulatory agent into the treatment regimen that posed substantial risks. This lack of transparency is believed to have led shareholders to invest at inflated company valuations.

The FDA's Clinical Hold

A critical turning point occurred on May 27, 2025, when Rocket announced that the FDA had placed a hold on the Phase 2 clinical study of RP-A501. This announcement followed serious adverse incidents, one of which tragically resulted in a patient's death. It was revealed that there were prior decisions to amend the protocol much earlier, yet investors were not informed until this dire event prompted a public acknowledgment. Consequently, Rocket's stock price saw a marked drop, plummeting approximately 37% from $6.27 to $2.33 in just one day, leading to significant losses for shareholders who acted on the misleading information.